Stephen Faraone

No bio available.

Financial relationships

  • Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Otsuka Pharmaceuticals
    Topic:
    ADHD treatment
    Date added:
    02/02/2026
    Date updated:
    02/04/2026
    Relationship end date:
    02/18/2027
  • Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Collegium Pharmaceutical
    Topic:
    ADHD treatment
    Date added:
    02/02/2026
    Date updated:
    02/04/2026
    Relationship end date:
    12/14/2026
  • Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    NIH
    Topic:
    ADHD
    Date added:
    02/02/2026
    Date updated:
    02/04/2026
    Relationship end date:
    02/07/2028
  • Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Noven Pharmaceuticals
    Topic:
    ADHD Evidence Project
    Date added:
    02/02/2026
    Date updated:
    02/04/2026
    Relationship end date:
    12/14/2026
  • Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Corium Pharmaceuticals
    Topic:
    ADHD Evidence Project
    Date added:
    02/02/2026
    Date updated:
    02/04/2026
    Relationship end date:
    12/14/2026
  • Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    European Commission
    Topic:
    TimeSpan ADHD
    Date added:
    02/02/2026
    Date updated:
    02/04/2026
    Relationship end date:
    12/21/2026
  • Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Tris Pharmaceuticals
    Topic:
    ADHD Treatment
    Date added:
    02/02/2026
    Date updated:
    02/04/2026
    Relationship end date:
    12/21/2026
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Axome
    Topic:
    ADHD
    Date added:
    02/02/2026
    Date updated:
    02/04/2026
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Collegium
    Topic:
    ADHD
    Date added:
    02/02/2026
    Date updated:
    02/04/2026
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Johnson & Johnson/Kenvue
    Date added:
    02/02/2026
    Date updated:
    02/04/2026

Pages

Return to RSS 124 Ken Altshuler, MD Grand Rounds In Psychiatry (FY26): “Rethinking the role of non-stimulants in ADHD treatment” (022526)

 

**Disclaimer**

This Continuing Medical Education (CME) Learning Management System, Ethos, includes individuals designated as 'faculty' for CME purposes. Please note that the term 'faculty' refers solely to their role as a contributor/planner within a CME activity and does not imply any formal affiliation with UT Southwestern Medical Center (UTSW). The display of names and credentials is intended for educational purposes only and does not necessarily indicate a professional or academic relationship with UTSW. Participants are encouraged to verify the affiliations and credentials of faculty members independently if further clarification is needed.